News
A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster drugs Ozempic and Wegovy from the drug shortage list, rejecting a challenge ...
Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...
Discover the latest business news including rising gas prices, Zepbound shipments, At Home bankruptcy, and the Federal Reserve meeting.
Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound
Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.
Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...
While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...
The clinical trial underscores Innovent’s ambition to deliver innovative obesity treatment to patients across Asia.
GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...
This article explains the main ways that Zepbound and Wegovy are alike and different. Your doctor can explain the benefits and risks of these and other treatment options based on your individual ...
Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients to adapt on the fly.
In February 2022, the 46-year-old from New Jersey had prediabetes and high blood pressure when ... the active ingredient in Eli Lilly’s Zepbound, at a dosage that cost $450 a month, then stepped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results